Eupraxia Pharmaceuticals
EPRX
8 hedge funds and large institutions have $4.55M invested in Eupraxia Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 3 closing their positions.
3% more capital invested
Capital invested by funds: $4.43M → $4.55M (+$113K)
0.2% more ownership
Funds ownership: 4.85% → 5.05% (+0.2%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$90.7K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$76.9K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.97K |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$3.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.88K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$1.39K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$304 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SC
1
Scotia Capital
Toronto,
Ontario, Canada
| $3.49M | +$76.9K | +29,230 | +2% |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $714K | +$14.6K | +5,543 | +2% |
|
3
Bank of Montreal
Toronto,
Ontario, Canada
| $126K | – | – | – |
|
|
4
Goldman Sachs
New York
| $90.7K | +$90.7K | +34,500 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $86.8K | +$8.97K | +3,410 | +12% |
|
|
1WA
6
180 Wealth Advisors
Federal Way,
Washington
| $34.2K | – | – | – |
|
|
TWC
7
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $3.83K | +$3.94K | +1,500 | New |
|
8
National Bank of Canada
Montreal,
Quebec, Canada
| $394 | +$394 | +150 | New |
|
|
9
JP Morgan Chase
New York
| – | -$4.88K | -1,892 | Closed |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$1.39K | -545 | Closed |
|
|
11
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$304 | -118 | Closed |
|
EPRX Hedge Fund Activity: Q3 2024 in Review
8 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q3 2024, worth a combined $4.55M — up 2.5% from $4.43M a quarter earlier.
Fund positioning in EPRX was balanced in Q3 2024: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $90.7K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $4.88K sold.
- 8 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $4.55M of Eupraxia Pharmaceuticals stock for Q3 2024, up 2.5% quarter-over-quarter.
- 3 funds opened new Eupraxia Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of 0 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q3 2024 was Goldman Sachs, an estimated $90.7K added.
- The largest Eupraxia Pharmaceuticals seller in Q3 2024 was JP Morgan Chase, an estimated $4.88K sold.
Based on aggregated 13F filings for Q3 2024.